FRα peptide plus Adjuvant (GM-CSF)
FRV-004
Phase 2 mab terminated
Quick answer
FRα peptide plus Adjuvant (GM-CSF) for Platinum Sensitive Ovarian Cancer is a Phase 2 program (mab) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Marker Therapeutics
- Indication
- Platinum Sensitive Ovarian Cancer
- Phase
- Phase 2
- Modality
- mab
- Status
- terminated